Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and efavirenz

lapatinib has been researched along with efavirenz in 3 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(efavirenz)		Trials
(efavirenz)		Recent Studies (post-2010) (efavirenz)
1,9193051,4423,1106311,611

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)efavirenz (IC50)
Chain A, POL POLYPROTEINHuman immunodeficiency virus 10.2612
Chain A, POL POLYPROTEINHuman immunodeficiency virus 10.2612
Chain B, POL POLYPROTEINHuman immunodeficiency virus 10.2612
Chain A, POL POLYPROTEINHuman immunodeficiency virus 10.2612
Chain B, POL POLYPROTEINHuman immunodeficiency virus 10.2612
Chain A, Pol PolyproteinHuman immunodeficiency virus 10.2612
Chain B, Pol PolyproteinHuman immunodeficiency virus 10.2612
Prothrombin Bos taurus (cattle)0.022
Gag-Pol polyproteinHIV-1 M:B_HXB2R0.1852
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)0.02
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)0.018
Microsomal triglyceride transfer protein large subunitHomo sapiens (human)0.054
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)0.004
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 Human immunodeficiency virus 10.0035
Reverse transcriptase/RNaseH Human immunodeficiency virus 10.1627
Reverse transcriptase Human immunodeficiency virus 10.0643

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1

Reviews

2 review(s) available for lapatinib and efavirenz

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022

Other Studies

1 other study(ies) available for lapatinib and efavirenz

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013